Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Executive Committee
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: 2014

Onxeo announces the great success of its share capital increase with shareholders’ preferential subscription rights

12/12/201409/11/2019

Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]

BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

04/08/201409/11/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma Publishes its first Shareholder Newsletter

04/29/201409/11/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Positive Phase II preliminary results of Validive® for the prevention of Severe Oral Mucositis in Head and Neck cancer patients

10/30/201409/06/2019

Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients […]

BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea

04/02/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®

04/01/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results

02/27/201409/04/2019

2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]

Publication of the 2013 Registration Document

04/08/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company

04/16/201409/04/2019

— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]

Quarterly information as of March 31, 2014

04/30/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be named Onxeo

05/21/201409/04/2019

 DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO  — Onxeo expected to have a […]

Registration of “Document E” and clearance of admission prospectus related to the proposed cross-border of Topotarget into BioAlliance Pharma

05/28/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Merger Plan with Topotarget: Pre-approval for the secondary listing of the shares of the merged company on NASDAQ OMX Copenhagen

06/20/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo

06/30/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, […]

BioAlliance Pharma strengthens its financial resources with the support of its top shareholder

07/18/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 – Final calendar for trading on both Euronext and NASDAQ OMX to be available soon

07/23/201409/04/2019

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, […]

Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen, Merger exchange to take place on August 5, 2014

07/24/201409/04/2019

Suite à l’annonce conjointe des deux sociétés le 23 juillet 2014, BioAlliance Pharma SA (Euronext Paris – BIO), société innovante […]

Key milestones and consolidated accounts – First six months 2014

08/01/201409/04/2019

Major evolution of the Company, renamed Onxeo, resulting from the merger between BioAlliance Pharma and Topotarget Good progress of the […]

Onxeo attends InvestorDagen 2014, the largest Danish private investor event

09/19/201409/04/2019

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan […]

Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance”

09/25/201409/04/2019

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]

Quarterly Information as of September 30, 2014

11/06/201409/04/2019

Quarterly Information as of September 30, 2014 – Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named […]

Onxeo Launches a Rights Issue With Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million)

11/17/201409/04/2019

Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen – ONXEO or “the Company”), an innovative biopharmaceutical company specialized in the development […]

Onxeo confirms receipt of the $25M milestone payment on Beleodaq®

11/13/201410/14/2018

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]

Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag® in primary liver cancer

11/24/201410/14/2018

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, […]

Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium

10/10/201410/14/2018

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, […]

Onxeo strengthens Beleodaq® patent protection in the U.S. until 2027

08/28/201410/14/2018

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan […]

BioAlliance Pharma announces the launch of Sitavig® in the United States by its partner Innocutis and the granting of a new U.S. Sitavig® patent

07/21/201410/14/2018

BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

FDA approval of Beleodaq™ (belinostat)

07/03/201410/14/2018

• Accelerated Approval of Topotarget’s Beleodaq™ for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma • Early […]

Execution of a license agreement with EMS for Sitavig® in Brazil

06/25/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma strengthens Livatag® patent protection in Japan until 2032

06/10/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer

05/19/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma announces major achievements on Validive®: Enrollment completion in the international Phase II trial with Validive® in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting

05/05/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

04/14/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®

03/31/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization

03/19/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major […]

BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan

02/04/201410/13/2018

Paris, February 4, 2014 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan […]

Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent

02/18/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]

FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments

01/23/201410/13/2018

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology, announced today that […]

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2022 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress